BMC gastroenterology · 2025
Impact of cholecystectomy on Metabolic dysfunction-Associated Steatotic Liver Disease and metabolic syndrome: a 6-month prospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bahri Mohammad Hadi, Navabian Susan, Akbari Homa, Bagherpour Javad Zebarjadi, Bozorgmehr Ramin, Mohammaditabar Mahdi
Аннотация
BACKGROUND: Cholecystectomy, a common surgery, may cause metabolic changes linked to bile acid metabolism. Early studies suggest a possible link between cholecystectomy and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and metabolic syndrome, but findings are inconclusive. This 6-month study aimed to assess how elective cholecystectomy affects metabolic syndrome development and MASLD progression in a Middle Eastern population.
METHODS: Participants included 51 patients undergoing elective cholecystectomy and 49 matched controls. MASLD grade and metabolic syndrome status were assessed at baseline and six months post-intervention using ultrasonography and standard clinical criteria.
RESULTS: A total of 100 patients were included in the present study, with 51 assigned to the cholecystectomy group and 49 to the control group. Over a six-month follow-up period, individuals in the cholecystectomy group experienced a significant decrease in body mass index (BMI) (p < 0.05) and fasting blood sugar (FBS) levels (p < 0.05). However, this group also exhibited a significant increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p < 0.05). In contrast, the control group showed significant improvements in FBS (p < 0.05) and HDL cholesterol levels (p < 0.05). Logistic regression analysis revealed that undergoing cholecystectomy was linked to a higher likelihood of developing metabolic syndrome (OR = 9.63, p < 0.05).
CONCLUSIONS: Our findings highlight the potential metabolic implications of cholecystectomy. Cholecystectomy was associated with reduced BMI and improved fasting glucose but significantly increased blood pressure over 6 months. Highlighting the need for careful metabolic monitoring post-surgery.
METHODS: Participants included 51 patients undergoing elective cholecystectomy and 49 matched controls. MASLD grade and metabolic syndrome status were assessed at baseline and six months post-intervention using ultrasonography and standard clinical criteria.
RESULTS: A total of 100 patients were included in the present study, with 51 assigned to the cholecystectomy group and 49 to the control group. Over a six-month follow-up period, individuals in the cholecystectomy group experienced a significant decrease in body mass index (BMI) (p < 0.05) and fasting blood sugar (FBS) levels (p < 0.05). However, this group also exhibited a significant increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p < 0.05). In contrast, the control group showed significant improvements in FBS (p < 0.05) and HDL cholesterol levels (p < 0.05). Logistic regression analysis revealed that undergoing cholecystectomy was linked to a higher likelihood of developing metabolic syndrome (OR = 9.63, p < 0.05).
CONCLUSIONS: Our findings highlight the potential metabolic implications of cholecystectomy. Cholecystectomy was associated with reduced BMI and improved fasting glucose but significantly increased blood pressure over 6 months. Highlighting the need for careful metabolic monitoring post-surgery.